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Abstract
Background Parathyroidectomy (PTx) is the treatment of choice for end-stage renal disease (ESRD) patients with
therapy-resistant hyperparathyroidism (HPT). The optimal timing of PTx for ESRD-related HPT—before or after
kidney transplantation (KTx)—is subject of debate.
Methods Patients with ESRD-related HPT who underwent both PTx and KTx between 1994 and 2015 were included
in a multicenter retrospective study in four university hospitals. Two groups were formed according to treatment
sequence: PTx before KTx (PTxKTx) and PTx after KTx (KTxPTx). Primary endpoint was renal function (eGFR,
CKD-EPI) between both groups at several time points post-transplantation. Correlation between the timing of PTx
and KTx and the course of eGFR was assessed using generalized estimating equations (GEE).
Results The PTxKTx group consisted of 102 (55.1%) and the KTxPTx group of 83 (44.9%) patients. Recipient age,
donor type, PTx type, and pre-KTx PTH levels were significantly different between groups. At 5 years after
transplantation, eGFR was similar in the PTxKTx group (eGFR 44.5 ± 4.0 ml/min/1.73 m2) and KTxPTx group
(40.0 ± 6.4 ml/min/1.73 m2, p = 0.43). The unadjusted GEE model showed that timing of PTx was not correlated
with graft function over time (mean difference -1.0 ml/min/1.73 m2, 95% confidence interval -8.4 to 6.4,
p = 0.79). Adjustment for potential confounders including recipient age and sex, various donor characteristics, PTx
type, and PTH levels did not materially influence the results.
Conclusions In this multicenter cohort study, timing of PTx before or after KTx does not independently impact graft
function over time.
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Abbreviations
PTx Parathyroidectomy
ESRD End-stage renal disease
HPT Hyperparathyroidism
KTx Kidney transplantation
eGFR Estimated glomerular filtration rate
GEE Generalized estimating equations
CI Confidence interval
SEM Standard error of the mean
PTH Parathyroid hormone
DHSG Dutch Hyperparathyroidism Study Group
PNF Primary non-function
CKD-EPI Chronic Kidney Disease Epidemiology
Collaboration
RLN Recurrent laryngeal nerve
SSP Surgical site problems
HAP Hospital-acquired pneumonia
ICU Intensive care unit
PTxKTx Parathyroidectomy before kidney
transplantation
KTxPTx Parathyroidectomy after kidney
transplantation
HLA Human leukocyte antigen
Introduction
Hyperparathyroidism (HPT) is a common metabolic com-
plication in end-stage renal disease (ESRD) [1]. Both
before and after kidney transplantation (KTx), HPT has
been associated with adverse patient outcomes [2, 3].
Parathyroidectomy (PTx) is the treatment of choice for
patients with HPT refractory to pharmacological treatment
[4]. Multiple studies have shown that PTx is very effective
in lowering PTH levels in ESRD patients, and successful
PTx may reduce the risk of all-cause and cardiovascular
mortality in ESRD patients with severe uncontrolled HPT
[5, 6]. Since secondary HPT may regress in up to 57% of
patients with correction of mineral homeostasis after suc-
cessful KTx, PTx is often postponed in patients listed for
transplantation [7–9]. On the other hand, persistently ele-
vated parathyroid hormone (PTH) levels cause resistance
of the parathyroid to serum calcium levels due to reduced
expression of the calcium-sensing receptor [10, 11]. This
results in tertiary HPT: autonomous production of PTH
with subsequent hypercalcemia, which occurs in 25–50%
of patients after KTx [12, 13]. PTx is considered the only
definitive treatment for tertiary HPT [14]. The introduction
of calcimimetics in 2004 has reduced PTx rates and con-
tributed to prolonged exposure to elevated serum PTH
levels [15]. Previous studies suggest that a higher pre-KTx
PTH level is associated with accelerated estimated
glomerular filtration rate (eGFR) decline after KTx, and an
increased risk of graft failure [3, 16, 17]. Furthermore,
previous studies suggested a transient deterioration of renal
graft function after PTx [16, 18, 19].
These previous studies report discordant results and
arguments regarding the optimal timing of PTx in relation
to KTx. In this study, we aimed to assess the impact of the
sequence of KTx and PTx on the course of post-KTx renal
function in a large multicenter cohort of ESRD-related
HPT patients with long-term follow-up.
Materials and methods
Study design
We performed a multicenter retrospective cohort study in
patients who underwent both KTx and PTx. The Dutch
Hyperparathyroidism Study Group (DHSG) initiated a
multicenter retrospective database with data from four
academic centers in the Netherlands (University Medical
Center Groningen [UMCG], Academic Medical Center
Amsterdam [AMC], Erasmus Medical Center Rotterdam
[EMC], and Leiden University Medical Center [LUMC]).
We evaluated medical records of all patients who under-
went both a KTx and a PTx in these centers between 1994
and 2015. All patients were C18 years and diagnosed with
ESRD-related HPT. Patients were divided into two groups
according to treatment sequence: the PTxKTx group, who
underwent PTx before KTx, and the KTxPTx group, who
underwent PTx after KTx. When patients received more
than one kidney transplant, only the first KTx was taken
into account.
This study was approved by the local medical ethical
committee of all participating centers (METc 2014/077).
The study was performed according to the Helsinki Ethical
Principles.
Data collection
For all patients, we collected cause of ESRD, pre-trans-
plant dialysis status (preemptive or dialysis), history of
diabetes mellitus, donor age and sex, cold and warm
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ischemia times, number of HLA mismatches, primary non-
function (PNF), type of PTx (subtotal PTx or total PTx
with autotransplantation), and biochemistry. PNF was
defined as an eGFR\10 ml/min/1.73 m2 at 3 months after
KTx. Patients who reached ESRD (dialysis or re-trans-
plantation) during follow-up were denoted as having an
eGFR of 0 ml/min/1.73 m2 until end of follow-up at
5 years; patients who died during follow-up were censored.
The following biochemical measurements were recorded:
serum calcium, PTH, albumin, and creatinine prior to KTx
and PTx and at 3 months, 6 months, 1 year, 3 years, and
5 years after both KTx and PTx. For patients who under-
went KTx after 2014, only 3-year follow-up data are
available. eGFR was calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) in ml/
min/1.73 m2 [20]. Serum calcium and albumin were mea-
sured using routine laboratory techniques. Serum calcium
was corrected for albumin levels according to the following
formula: adjusted total calcium (mg/dL) = measured cal-
cium (mg/dL) ? (0.8 * 4 - [albumin (g/dL)]). Reference
range for serum calcium was 2.20–2.60 mmol/L. Different
PTH assays were used among the four centers. UMCG:
until 2006: Nichols Institute Diagnostics, San Juan Capis-
trano, CA, USA; since February 2006: Immulite 2500,
Siemens Healthcare Diagnostics, Deerfield, IL, USA; and
the Cobas 3601 immunology analyzes Roche Diagnostics,
Mannheim, Germany. PTH values were recalculated
according to the conversion equation provided by the lab-
oratory. Reference values were 1.8–9.6 pmol/L. EMC:
Vitros ECi Assay, Ortho-Clinical Diagnostics, Inc., New
Jersey, USA. Reference range was 1.4–7.3 pmol/L. AMC:
Roche Cobas e602, Roche Diagnostics International Ltd,
Rotkreuz, Switzerland, with a reference range of
2.00–7.00 pmol/L. LUMC: Immulite 1000, Siemens
Healthcare Diagnostics, Deerfield, IL, USA, with a refer-
ence range of 0.7–8.0 pmol/L.
Primary and secondary endpoints
To analyze the impact of the timing of PTx on graft
function, the primary endpoint was eGFR at 5 years after
transplantation. We also analyzed serum-corrected cal-
cium, and PTH, graft failure and post-PTx complications,
including temporary palsy of the recurrent laryngeal nerve
(RLN), surgical site problems (SSP, including hematoma
and infection), hospital-acquired pneumonia (HAP),
intensive care unit (ICU) admission, and temporary
hypocalcaemia.
Data analyses and statistics
A power analysis was performed based on results of a
previous comparable study [21]. With 80% power and a
two-sided a = 0.05, a simple size of n = 120 is required to
detect a 20% difference in eGFR post-KTx. Statistical
analysis was performed using SPSS Statistics version 24.0
(IBM Corporation, Armonk, NY, USA); a P value of\0.05
was considered statistically significant.
Patient characteristics were compared between the two
groups (PTxKTx vs. KTxPTx) using Mann–Whitney U test
and Pearson’s Chi-square test where appropriate. Contin-
uous variables were reported as mean ± standard error of
the mean (SEM) or median with interquartile range (IQR).
Categorical variables were expressed as number (n) and
percentage (%).
To further study the impact of treatment sequence on
graft function over time, we established generalized esti-
mating equations (GEE) models with an exchangeable
correlations structure. Based on previous literature, recip-
ient age and sex, donor age and sex, type of donor (living
vs. deceased), total number of HLA mismatches, type of
PTx (total vs. subtotal), cold ischemia time, and pre-
transplant dialysis status (preemptive or dialysis) were
defined as potential important confounders prior to analysis
and were adjusted for in the multivariable GEE model.
Furthermore, baseline variables with P values\0.2 in the
univariate GEE analyses were included in multivariable
GEE model. Results of the GEE model are displayed as
estimates of the effects (B) and 95% confidence interval
(CI) with P value. In a sub-analysis, we also evaluated the
impact on eGFR in patients who underwent PTx shortly
after KTx (\1 year) or longer (C1 year) after KTx.
Results
Patient characteristics
A total of 185 patients were included: 102 (55.1%) patients
underwent PTx before KTx (PTxKTx group), while 83
(44.9%) underwent PTx after KTx (KTxPTx group)
(Fig. 1). Baseline patient and transplant characteristics are
presented in Table 1. Patients within the KTxPTx group
were significantly younger at the time of KTx than patients
in the PTxKTx group. Eight patients (4.3%) underwent
preemptive KTx; these patients were well equally dis-
tributed among the groups (n = 3 vs. n = 5, p = 0.31).
Median time from start dialysis until KTx was significantly
longer in the PTxKTx group compared to the KTxPTx
group (61 months [46–83 months] versus 36 months
[14–57 months], p\0.01). In the KTxPTx group, living
donor KTx was more common compared to the PTxKTx
group (26.5% vs. 6.9%, p = 0.006). Pre-KTx PTH levels
were significantly higher in the KTxPTx group (66
[34–127] pmol/L vs. 15 [4–35] pmol/L, p\0.001).
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Calcimimetics were used at some point during follow-up in
31.4% of the patients in the PTxKTx group, compared to
20.5% of the patients in de KTxPTx group (p = 0.18). Ten
patients (10.1%) developed primary non-function after
KTx in the PTxKTx group, compared to 17.9% in the
KTxPTx group (p = 0.13), and were excluded from further
analysis.
Patients with PTx before KTx
Patients in the PTxKTx group had a median pre-PTx serum
PTH level of 120 (73–186) pmol/L. Postoperatively, PTH
dropped with a median of 96 (83–99)% within 3 months.
Serum calcium levels corrected for albumin changed after
PTx from 10.1 (9.3–10.7) mg/dL to 9.1 (8.1–10.0) mg/dL
(p\0.01). Median time from PTx to KTx was 23 (11–38)
months (Fig. 2). Median PTH levels increased from 5.4
(2.2–14.7) pmol/L post-PTx to 15 (4–35) pmol/L at day of
admission for KTx (p = 0.006). Three months after KTx,
PTH levels dropped significantly to 11 (6–24) pmol/L
(p = 0.02). The course of eGFR after KTx is presented in
Fig. 3. In the PTxKTx group, 8.1% of patients had a
complication following PTx (Supplementary Table 1).
Patients with PTx after KTx
Patients in the KTxPTx group underwent PTx at median 30
(15–74) months after KTx (Fig. 2). Fifteen of the 83 patients
(18.1%) underwent PTx within 1 year after KTx. Median pre-
PTx PTH levels were significantly lower in the KTxPTX
group compared to the PTxKTX group (50 [26–122] pmol/L
vs. 120 [73–186] pmol/L, p\0.001). The median postopera-
tive PTH drop three months after PTx was 88 (63–96)% to 7.7
[2.7–17.1] pmol/L. Serum calcium levels corrected for albu-
min also decreased significantly after PTx, from 10.7
(9.8–11.6) mg/dL to 9.2 (8.4–9.9) mg/dL (p\0.01). The
eGFR course after KTx is depicted in Fig. 3. eGFR before and
after PTx is shown in Fig. 4. Fifteen (18.1%) of patients in the
KTxPTx group had a C25% decrease of eGFR at 3 months
after PTx. (20.7 ± 5.4 ml/min/1.73 m2 vs. 37.9 ± 3.2 ml/
min/1.73 m2, p = 0.01). At 1 year after PTx, eGFR was
similar to pre-PTx values. There were no significant differ-
ences in baseline characteristics between patients withC25%
decrease in eGFR versus patients with stable eGFR after PTx
(Supplementary Table 2). The complication rate in the
KTxPTx group was 5.0% and not significantly different
compared to the PTxKTx group (p = 0.42).
Paents included
N = 185
PTx before KTx
N = 102
PTx aer KTx
N = 83
PTx < 1 year aer KTx
N = 18
PTx ≥ 1 year aer KTx
N = 65
Paents who underwent
PTx and KTx
N = 206
Paents excluded due to
missing data
N = 21
Fig. 1 Flowchart of included patients. PTx parathyroidectomy, KTx kidney transplantation
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Table 1 Baseline characteristics
Total PTx before KTx PTx after KTx P value
Patient characteristics
Number of patients 185 102 83
Center 0.000
UMCG 55 (29.7) 33 (32.4) 22 (26.5)
LUMC 20 (10.8) 15 (8.1) 5 (6.0)
AMC 62 (33.5) 46 (45.1) 16 (19.3)
EMC 48 (25.9) 8 (7.8) 40 (48.2)
Age at PTx, y 46 (33–57) 47 (33–58) 45 (34–57) 0.85
Age at KTx, y 47 (31–58) 49 (37–60) 38 (28–54) 0.001
Sex, male/female 49.2/50.8 45.1/54.9 54.2/45.8 0.22
ESRD cause 0.08
Alport syndrome 5 (2.7) 2 (2.0) 3 (3.7)
DM 6 (3.3) 3 (3.0) 3 (3.7)
Focal segmental glomerulosclerosis 17 (9.3) 10 (10.0) 7 (8.5)
Hypertension 37 (20.3) 26 (26.0) 11 (13.4)
IgA nephropathy 14 (7.7) 5 (5.0) 9 (11.0)
Membranous glomerulonephritis 13 (7.1) 7 (7.0) 6 (7.3)
Henoch–Scho¨nlein disease 1 (0.5) 0 (0.0) 1 (1.2)
Nephrotic syndrome 10 (5.5) 4 (4.0) 6 (7.3)
Polycystic kidney disease 20 (11.0) 5 (5.0) 15 (18.3)
Pyelonephritis 15 (8.2) 9 (9.0) 6 (7.3)
Post-renal obstruction 10 (5.5) 5 (5.0) 5 (6.1)
SLE 1 (0.5) 1 (1.0) 0 (0.0)
Unknown 33 (18.1) 23 (23.0) 10 (12.2)
Diabetes mellitus 0.27
Type 1 7 (3.8) 3 (3.0) 4 (4.8)
Type 2 18 (9.8) 7 (6.9) 11 (13.3)
PTH prior to KTx, pmol/L 28 (8–65) 14.9 (4.4–34) 65.7 (34–127) 0.000
Calcium prior to KTx, mmol/L 2.49 (2.32–2.64) 2.40 (2.24–2.52) 2.61 (2.44–2.72)
Donor characteristics
Donor type 0.006
DCD 60 (32.4) 41 (40.2) 19 (22.9)
DBD 81 (43.8) 48 (47.1) 33 (39.8)
Living related 29 (15.7) 7 (6.9) 22 (26.5)
Living unrelated 15 (8.1) 6 (5.9) 9 (10.8)
Donor age, y 50 (40–57) 53 (43–58) 47 (37–54) 0.14
Gender, male/female 47.9/52.1 43.3/55.7 57.7/42.3 0.27
Transplant characteristics
Cold ischemia time, h 18 (14–23) 18 (14–23) 18 (13–23) 0.85
Warm ischemia time, min 32 (25–40) 34 (25–42) 30 (25–39) 0.23
Total HLA mismatches 0.50
0 37 (24.7) 22 (25.0) 15 (24.2)
1 14 (9.3) 5 (5.7) 9 (14.5)
2 28 (18.7) 17 (19.3) 11 (17.7)
3 41 (27.3) 26 (29.5) 15 (24.2)
4 17 (11.3) 12 (13.6) 5 (8.1)
5 6 (4.0) 3 (3.4) 3 (4.8)
6 7 (4.7) 3 (3.4) 4 (6.5)
Preemptive transplantation 8 (4.3) 3 (2.9) 5 (6.0) 0.31
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Impact of PTx timing on post-KTx eGFR
The unadjusted GEE model showed that the timing of PTx
was not associated with graft function over time (mean
difference -1.0 ml/min/1.73 m2, 95% confidence interval
[CI] -8.4 to 6.4, p = 0.79), Table 2). In a model adjusted
for donor variables including donor type, donor gender,
total number of HLA mismatches, whether the transplan-
tation was preemptive or post-dialysis, donor age, and cold
ischemia time, the mean difference in eGFR was -4.8 ml/
min/1.73 m2 (96% CI -15.4 to 5.7, p = 0.37). Finally, we
constructed a third model adjusted for pre-defined poten-
tially relevant covariates and all baseline variables with a
P value of\0.2 in univariate analysis. This analysis also
showed that the course of eGFR over time was not sig-
nificantly different between patients who underwent PTx
before KTx or after KTx (Table 2).
Discussion
This large multicenter cohort study showed that in patients
with ESRD-related HPT, the timing of parathyroidectomy
(PTx) before or after kidney transplantation (KTx) does not
independently impact the long-term course of kidney
function after KTx.
This finding is in line with a previous single-center study
that reported no significant difference in graft function at
various time points after KTx between patients who
underwent PTx before or after KTx [21]. With 185
patients, our study population is almost twice as large and
meets the pre-specified sample size sufficient to detect a
20% difference in eGFR after PTx. Moreover, our follow-
up was 5 years compared to 12 months in the previous
study. Our results are at variance with two smaller retro-
spective studies. One study (Schwarz et al. [19]) investi-
gating 76 kidney transplant recipients who underwent PTx
showed that nearly half of these patients had an eGFR
decline of more than 20%; however, renal function
returned to pre-PTx values at 1 year post-PTx, in line with
our results. In this study, patients who had this deteriora-
tion of graft function had a greater delta PTH decline after
PTx compared to those without a deterioration [19]. In the
current study, no significant differences were found
between the stable eGFR group and the patients who had
an eGFR decline C25%. This is likely due to the small
number of patients with such eGFR decline post-PTx in our
cohort. Parikh et al. also reported a significant but transient
decline in eGFR post-PTx [16]. Another recent study by
Littbarski et al. [22] suggested that, particularly early
(\1 year) after transplantation, PTx contributes to renal
function loss. Despite the larger sample size in our study
Table 1 continued
Total PTx before KTx PTx after KTx P value
PTx
PTx type 0.008
Total PTx 93 (50.3) 57 (55.9) 36 (43.4)
Subtotal 63 (33.1) 25 (24.5) 38 (45.8)
Other 29 (15.7) 20 (19.6) 9 (10.8)
Data are presented as median (IQR) or number (%)
UMCG University Medical Center Groningen, LUMC Leiden University Medical Center, AMC Academic Medical Center, EMC Erasmus
Medical Center, ESRD end-stage renal disease, SLE systemic lupus erythematosus, PTH parathyroid hormone, DCD donation after circulatory
death, DBD donation after brain death, HLA human leukocyte antigen
Fig. 2 Schematic representation of the study cohort. Time between PTx and KTx is indicated as median (interquartile range). PTx
parathyroidectomy, KTx kidney transplantation
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(n = 185 vs. 123 patients with long-term follow-up), we
could not reproduce this result: neither in patients with
early PTx (although only 15 patients underwent PTx in the
first year post-transplant in our study), nor in those with
later PTx after KTx. Our findings thus challenge the rec-
ommendation by Littbarski et al. to conduct PTx before
KTx in all patients. The finding of Lou et al. [7] that up to
57% of patients show regression of their HPT within
2 years after a KTx supports the recommendation to wait
for 1–2 years after KTx before proceeding with PTx.
We found that pre-PTx PTH levels were significantly
lower in the group of patients who underwent PTx after
KTx. This could be partly explained by improved renal
function resulting in at least partly restored mineral
homeostasis [23]. Alternatively, the difference in pre-KTx
PTH values could result from the fact that patients with
more severe HPT were more likely to undergo PTx prior to
receiving a kidney transplant.
Factors determining the post-transplant eGFR course
include donor and recipient age and sex, history of dia-
betes, cold ischemia time, total number of HLA mis-
matches, and donor type [24]. Our results indicate that the
timing of PTx in relation to KTx does not importantly
impact the course of renal function. Therefore, other fac-
tors than impact on graft function should be taken into
account when deciding on a treatment plan and sequence in
Fig. 3 eGFR values after KTx.
eGFR, estimated glomerular
filtration rate; KTx kidney
transplantation, PTx
parathyroidectomy
Fig. 4 Pre- and post-PTx eGFR values of patients in the KTxPTx
group. PTx parathyroidectomy, eGFR estimated glomerular filtra-
tion rate, KTx kidney transplantation
Table 2 Generalized estimating equations analyses of the relation-
ship between sequence of PTx/KTx and eGFR over time
Model B 95% CI P value
Unadjusteda -1.04 -8.4 to 6.4 0.79
Adjusted model Ib -4.8 -15.4 to 5.8 0.37
Adjusted model IIc 4.5 -14.2 to 23.3 0.64
aUnadjusted model: correlation between sequence of PTx and KTx
and eGFR over time
bThe above model adjusted donor variables including donor type,
donor gender, total number of HLA mismatches, whether the trans-
plantation was preemptive or post-dialysis, donor age, and cold
ischemia time
cThe above model adjusted for donor type, donor age and sex, total
number of HLA mismatches, pre-transplant dialysis status (preemp-
tive or dialysis), cold ischemia time, recipient age and sex, type of
PTx, center, cause of end-stage renal disease (ESRD), dialysis vin-
tage, before versus after introduction of calcimimetics, PTH at
baseline
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patients with ESRD-related HPT. These factors include the
severity of symptoms, quality of life, patient preference,
level of calcium, phosphate and PTH, bone density, and the
anticipated chance of spontaneous regression of HPT after
KTx [25]. HPT is associated with an increased risk of
cardiovascular disease events and mortality [3, 26].
Therefore, when KTx is expected in the near future and the
abovementioned factors are taken into account, we suggest
to be reticent to proceed with PTx. Based on our results, it
seems safe for patients with persistent HPT after KTx to
undergo PTx, at least regarding renal function and com-
parable complication rates between the two groups (Sup-
plementary Table 2). Additionally, there was no significant
difference in HPT recurrence rate between both study
groups. In a recent study, male sex and white race were
predictors of a more pronounced decline in PTH 2 years
after KTx, whereas obesity, dialysis vintage, and delayed
graft failure were risk factors for persisting HPT after KTx
[7]. Studies aimed at identifying predictors of PTH nor-
malization after KTx support a personalized approach
toward the timing of PTx in relation to KTx.
Several limitations of our study should be addressed.
Inherent to the retrospective nature of our study, selection
bias and residual confounding cannot be excluded. Many
patient-specific factors have likely driven the decision on
PTx timing. We were therefore not able to determine the
exact indication criteria for PTx in this multicenter retro-
spective study cohort. It is, however, probable that patients
with more severe disease were more likely to have
undergone parathyroidectomy prior to their kidney trans-
plantation compared to the patients with less severe dis-
ease. Prospective studies are needed to provide more solid
evidence. Second, our results obtained in four centers in the
Netherlands might not be extrapolated to other countries
with different healthcare infrastructure and guidelines.
Third, we could not take the introduction of calcimimetics
into account, which has significantly changed management
of HPT [15].
In conclusion, we found that the sequence of KTx and
PTx does not independently influence post-transplant graft
function. We suggest that PTx can be safely performed
after KTx in patients with persistent HPT. Therefore, we
support the approach to postpone PTx until after KTx if
transplantation is expected within a reasonable timeframe
in order to allow spontaneous HPT regression, which
occurs in a considerable proportion of patients. Our find-
ings support a personalized approach for HPT patients
listed for kidney transplantation.
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